Targeting steroid sulfatase to treat advanced prostate cancer
Therapeutic targeting steroid sulfatase for advanced prostate cancer
This study is looking at how a protein called steroid sulfatase affects advanced prostate cancer that doesn't respond to common treatments, and it aims to create new medicines that could lower hormone levels and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10860988 on NIH RePORTER |
What this research studies
This research investigates the role of steroid sulfatase (STS) in advanced prostate cancer, particularly in cases resistant to current treatments like enzalutamide and abiraterone. The study aims to understand how STS contributes to the production of androgens, which can fuel cancer growth despite treatment. By developing small molecule inhibitors that target STS, the research seeks to reduce androgen levels and improve treatment outcomes for patients with castration-resistant prostate cancer. Patients may benefit from new therapeutic options that specifically address this resistance mechanism.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have shown resistance to standard treatments.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment approach that enhances the effectiveness of existing therapies for advanced prostate cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success with this approach.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Gao, Allen C. — University of California at Davis
- Study coordinator: Gao, Allen C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.